Intercell FY09 Revenues Up
Intercell has posted a net loss of EUR18.37m for the full year 2009, or EUR0.39 per diluted share, compared to net income of EUR17.17m, or EUR0.37 per diluted
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
According to the agreement, Cytovance will lead the cell culture process optimization, recovery and purification development, CGMP manufacturing and also technical and regulatory support to facilitate Selexys’ clinical